Csx28 is a membrane pore that enhances CRISPR-Cas13b–dependent antiphage defense
Author(s) -
Arica R. VanderWal,
Jung-Un Park,
Bogdan Polevoda,
Julia K. Nicosia,
Adrian M. Molina Vargas,
Elizabeth H. Kellogg,
Mitchell R. O’Connell
Publication year - 2023
Publication title -
science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 12.556
H-Index - 1186
eISSN - 1095-9203
pISSN - 0036-8075
DOI - 10.1126/science.abm1184
Subject(s) - microbiology and biotechnology , transmembrane protein , effector , rnase p , rna , biology , ribonuclease , crispr , membrane protein , inner membrane , chemistry , membrane , biochemistry , gene , receptor , mitochondrion
Type VI CRISPR-Cas systems use RNA-guided ribonuclease (RNase) Cas13 to defend bacteria against viruses, and some of these systems encode putative membrane proteins that have unclear roles in Cas13-mediated defense. We show that Csx28, of type VI-B2 systems, is a transmembrane protein that assists to slow cellular metabolism upon viral infection, increasing antiviral defense. High-resolution cryo-electron microscopy reveals that Csx28 forms an octameric pore-like structure. These Csx28 pores localize to the inner membrane in vivo. Csx28's antiviral activity in vivo requires sequence-specific cleavage of viral messenger RNAs by Cas13b, which subsequently results in membrane depolarization, slowed metabolism, and inhibition of sustained viral infection. Our work suggests a mechanism by which Csx28 acts as a downstream, Cas13b-dependent effector protein that uses membrane perturbation as an antiviral defense strategy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom